These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. CDK inhibitors in cancer therapy: what is next? Malumbres M; Pevarello P; Barbacid M; Bischoff JR Trends Pharmacol Sci; 2008 Jan; 29(1):16-21. PubMed ID: 18054800 [TBL] [Abstract][Full Text] [Related]
5. Carbonic anhydrase inhibition as a cancer therapy: a review of patent literature, 2007 - 2009. Poulsen SA Expert Opin Ther Pat; 2010 Jun; 20(6):795-806. PubMed ID: 20476848 [TBL] [Abstract][Full Text] [Related]
6. Small molecule c-Met kinase inhibitors: a review of recent patents. Porter J Expert Opin Ther Pat; 2010 Feb; 20(2):159-77. PubMed ID: 20100000 [TBL] [Abstract][Full Text] [Related]
7. Progress in the evaluation of CDK inhibitors as anti-tumor agents. McInnes C Drug Discov Today; 2008 Oct; 13(19-20):875-81. PubMed ID: 18639646 [TBL] [Abstract][Full Text] [Related]
8. Pim kinase inhibitors: a survey of the patent literature. Morwick T Expert Opin Ther Pat; 2010 Feb; 20(2):193-212. PubMed ID: 20100002 [TBL] [Abstract][Full Text] [Related]
9. Inhibitors of Cdc25 phosphatases as anticancer agents: a patent review. Lavecchia A; Di Giovanni C; Novellino E Expert Opin Ther Pat; 2010 Mar; 20(3):405-25. PubMed ID: 20166845 [TBL] [Abstract][Full Text] [Related]
10. Cyclin-dependent kinases as targets for cancer therapy. Senderowicz AM Cancer Chemother Biol Response Modif; 2002; 20():169-96. PubMed ID: 12703205 [TBL] [Abstract][Full Text] [Related]
11. Platelet-derived growth factor receptor tyrosine kinase inhibitors: a review of the recent patent literature. Dai Y Expert Opin Ther Pat; 2010 Jul; 20(7):885-97. PubMed ID: 20509775 [TBL] [Abstract][Full Text] [Related]
12. Cyclin-dependent kinase modulators: a novel class of cell cycle regulators for cancer therapy. Senderowicz AM Cancer Chemother Biol Response Modif; 2001; 19():165-88. PubMed ID: 11686013 [TBL] [Abstract][Full Text] [Related]
13. Phospholipase A2 inhibitors as potential therapeutic agents for the treatment of inflammatory diseases. Magrioti V; Kokotos G Expert Opin Ther Pat; 2010 Jan; 20(1):1-18. PubMed ID: 20021282 [TBL] [Abstract][Full Text] [Related]
14. Cyclin-dependent kinase and protein kinase C inhibitors: a novel class of antineoplastic agents in clinical development. Kaubisch A; Schwartz GK Cancer J; 2000; 6(4):192-212. PubMed ID: 11038138 [TBL] [Abstract][Full Text] [Related]
15. Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014). Malínková V; Vylíčil J; Kryštof V Expert Opin Ther Pat; 2015; 25(9):953-70. PubMed ID: 26161698 [TBL] [Abstract][Full Text] [Related]
16. Recent developments on JAK2 inhibitors: a patent review. Kiss R; Sayeski PP; Keserũ GM Expert Opin Ther Pat; 2010 Apr; 20(4):471-95. PubMed ID: 20205617 [TBL] [Abstract][Full Text] [Related]
18. [Prevention of chemotherapy-induced alopecia by cyclin-dependant kinase inhibitors]. Meijer L; Knockaert M; Damiens E Bull Cancer; 2001 Apr; 88(4):347-50. PubMed ID: 11371368 [TBL] [Abstract][Full Text] [Related]
19. Recent advances and new directions in the discovery and development of cyclin-dependent kinase inhibitors. Fischer PM Curr Opin Drug Discov Devel; 2001 Sep; 4(5):623-34. PubMed ID: 12825457 [TBL] [Abstract][Full Text] [Related]